Erlonat
Erlonat (Erlotinib 100/150 mg) — Natco EGFR-TKI for non-small cell lung cancer with sensitising EGFR mutations and advanced pancreatic cancer with gemcitabine.
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
Răspuns rapid
Erlonat — Erlotinib 100/150 mg (Natco Pharma). EGFR-TKI for non-small cell lung cancer with EGFR sensitising mutations (exon 19 deletions, L858R), advanced pancreatic cancer (with gemcitabine).
Ce beneficii oferă MedsBase:
- producător certificat WHO-GMP
- Ambalaj discret în plic simplu
- Livrare în toată lumea
- Evaluat de peste 1.400 de clienți (citește recenziile)
📦 Garanția de retransmitere: dacă comanda dvs. nu a ajuns în 20 de zile lucrătoare de la expediere, o retransmitem fără costuri suplimentare. Citește politica.
De ce să comanzi de la MedsBase
Erlonat ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical — missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.
Class effect: acneiform rash in 70-90% — usually correlates with response. ILD risk <1% but potentially fatal — investigate any unexplained dyspnoea, cough, or fever. Take on empty stomach (food doubles bioavailability — risk of toxicity).
Întrebări frecvente
What is a TKI?
Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib/erlotinib; multikinase for sorafenib/sunitinib; BCR-ABL for nilotinib/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4/6 for palbociclib).
Side effects?
Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.
Interacțiuni medicamentoase?
Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) drop levels and risk treatment failure.
Take with food?
Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule — confirm with prescribing oncologist.
What about response monitoring?
Imaging (CT/MRI/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.
Resistance?
TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.
Ce fac dacă uit o doză?
Take when you remember if same day if >6 hours from next dose. Otherwise skip — do not double up. Specific instructions vary by drug; confirm with your oncology team.
Sarcină?
All TKIs are teratogenic — effective contraception during and for at least 4-6 months after for both partners.
Cardiac monitoring?
Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up — QT prolongation.
Cost-effectiveness?
Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
More options in Anti Cancer Medication
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Concentrație | 100 mg, 150 mg |
|---|---|
| Cantitate | 30 Tablet/s, 60 Tablet/s |
| Formă farmaceutică | Comprimat/e |
| Producător | Natco Pharma |
| Indicație | Non-small cell lung cancer, Pancreatic cancer |
| Brand generic | Erlotinib |
Erlonat
Întrebări și răspunsuri
Erlonat
Produse similare
Recenzii
Nu există recenzii încă